Orgenesis

OverviewSuggest Edit

Orgenesis is a development stage company with a novel therapeutic approach in the treatment of diabetes by correcting malfunctioning organs with new functional tissues created from the patient’s own existing organs. Orgenesis employs a molecular and cellular approach directed at converting liver cells into functional insulin-producing cells as a treatment for diabetes. This new therapeutic approach is called Autologous Insulin Producing (AIP) cell transplantation.
TypePrivate
Founded2008
Websiteorgenesis.com

Latest Updates

Employees (est.) (Nov 2018)231(+125%)
Revenue (FY, 2018)$18.7 M(+85%)

Key People/Management at Orgenesis

Guy Yachin

Guy Yachin

Director
David Sidransky

David Sidransky

Director
Yaron Adler

Yaron Adler

Director
Ashish Nanda

Ashish Nanda

Director
Show more

Orgenesis Office Locations

Orgenesis has an office in Germantown
Germantown, US
Goldrenrod Building, 20271 Goldenrod Ln
Show all (1)

Orgenesis Financials and Metrics

Summary Metrics

Founding Date

2008
Show all financial metrics

Orgenesis Revenue

Orgenesis's revenue was reported to be $18.66 m in FY, 2018
USD

Revenue (Q2, 2019)

7.8m

Gross profit (Q2, 2019)

2.8m

Gross profit margin (Q2, 2019), %

36.4%

Net income (Q2, 2019)

5.8m

EBIT (Q2, 2019)

5.3m

Cash (30-Jun-2019)

16.1m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

3.0m6.4m10.1m18.7m

Revenue growth, %

115%

Cost of goods sold

3.9m7.7m6.8m10.8m

Gross profit

(906.0k)(1.3m)3.3m7.8m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

820.4k936.2k1.5k1.1k1.8k1.9m2.3m2.6m2.6m4.0m6.2m7.3m7.8m

Cost of goods sold

973.0k1.3m1.5k2.0k1.8k1.9m1.1m1.9m1.6m2.2m3.4m4.3m4.9m

Gross profit

(152.6k)(389.5k)40.0(832.0)20.0(53.0k)1.2m695.0k992.0k1.8m2.8m3.0m2.8m

Gross profit Margin, %

(19%)(42%)3%(73%)1%(3%)51%27%38%45%46%41%36%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

50.8k1.3m4.2m891.0k3.5m16.1m

Accounts Receivable

1.2m1.2m1.3m4.2m

Inventories

301.0k400.0k725.0k1.7m

Current Assets

97.7k2.2m8.2m4.2m7.3m30.3m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

237.4k12.4k1.5m520.1k185.0k264.3k933.0474.0270.03.9m658.0k762.0k4.2m4.5m16.7m14.4m16.1m

Accounts Receivable

278.7k847.5k1.7k1.7k1.8k1.5m3.0m2.1m1.2m1.3m4.2m6.0m6.9m

Inventories

259.1k264.7k418.0413.0391.0614.0k904.0k965.0k881.0k1.2m1.7m2.0m2.2m

Current Assets

276.7k134.6k1.6m1.2m2.5m3.0m5.1k5.1k5.3k7.4m6.1m5.7m8.6m13.7m24.7m23.9m27.1m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(5.5m)(5.5m)(4.5m)(9.2m)(12.4m)

Depreciation and Amortization

3.3k1.2m1.6m

Inventories

301.0k

Accounts Payable

3.0k1.0m1.5m1.1m(933.0k)
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(709.3k)(3.5m)790.2k(1.9m)(3.5m)225.0(3.7k)(6.3k)(9.0m)(9.6m)(11.5m)(5.5m)(8.0m)(12.2m)(8.4m)(14.3m)

Depreciation and Amortization

867.0392.9k408.4k328.0482.0408.0381.0k

Inventories

(32.8k)264.7k418.0413.0391.0(134.0k)(366.0k)

Accounts Payable

32.0k191.5k237.0k524.3k310.6k659.6k2.9k587.0637.0(1.3m)(1.2m)980.0k1.8m
USDY, 2019

Financial Leverage

5 x
Show all financial metrics

Orgenesis Online and Social Media Presence

Embed Graph

Orgenesis News and Updates

Orgenesis to Present at the 2019 Janney Healthcare Conference

Presentation Scheduled for Tuesday, September 10th at 12:35 PM Eastern Time Presentation Scheduled for Tuesday, September 10th at 12:35 PM Eastern Time

Orgenesis Reorganizes Its Israel and Korea Subsidiaries to Support Continued Growth

GERMANTOWN, Md., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS), a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development services through its subsidiary MTH Global, Inc., as well as localized point-of-care development and processin…

Orgenesis Second Quarter 2019 Revenue Increases 95% to a Record $7.8 Million

Generates $1 Million in Sales through New POCare Platform

Orgenesis shares soar 19% premarket after FDA grants orphan designation to insulin tech

Orgenesis Inc. shares soared 19% in premarket trade Monday, after the U.S. Food and Drug Administration granted Orphan Drug Designation to the company's Autologous Insulin Producing cells as a cell replacement therapy for the treatment of severe hypoglycemia-prone diabetes resulting from total panc…

Orgenesis First Quarter 2019 Revenue Increases 177% to a Record $7.3 Million

Company Expands Point of Care Platform; Benefits from Growing Cell and Gene Therapy Market Company Expands Point of Care Platform; Benefits from Growing Cell and Gene Therapy Market

Orgenesis Announces Collaboration Agreement with Columbia University to Develop Cellular Vaccination Product Platform for Pancreatic, Hepatic and Cholangiocarcinoma Cancers

GERMANTOWN, Md., April 22, 2019 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS), a developer of advanced cell therapies, manufacturer and service provider, today announced that it has entered into an agreement with Columbia University, by which it will fund research to develop a cellular vaccina…
Show more

Orgenesis Frequently Asked Questions

  • When was Orgenesis founded?

    Orgenesis was founded in 2008.

  • Who are Orgenesis key executives?

    Orgenesis's key executives are Guy Yachin, David Sidransky and Yaron Adler.

  • How many employees does Orgenesis have?

    Orgenesis has 231 employees.

  • What is Orgenesis revenue?

    Latest Orgenesis annual revenue is $18.7 m.

  • What is Orgenesis revenue per employee?

    Latest Orgenesis revenue per employee is $80.8 k.

  • Who are Orgenesis competitors?

    Competitors of Orgenesis include Virta Health, Dr Lal PathLabs and Spark Therapeutics.

  • Where are Orgenesis offices?

    Orgenesis has an office in Germantown.

  • How many offices does Orgenesis have?

    Orgenesis has 1 office.